Paper: Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
Program: Oral and Poster Abstracts Type: Oral Session: 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Study Population, Human Hartmut Goldschmidt, MD 1,2, Uta Bertsch, MD 3,4 *, Ema Pozek 5 *, Axel Benner 6 *, Roland Fenk, MD, PhD 7 *, Britta Besemer, MD 8 *, Christine Hanoun 9 *, Roland Schroers, MD
